Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TrkC


Brief Information

Name:Neurotrophic tyrosine kinase receptor type 3
Target Synonym:Trk-C,NTRK3,NT-3 growth factor receptor,TrkC tyrosine kinase,Neurotrophic Receptor Tyrosine Kinase 3,Neurotrophic Tyrosine Kinase, Receptor, Type 3,GP145-TrkC,TRKC,ETS Related Protein-Neurotrophic Receptor Tyrosine Kinase Fusion Protein,Tyrosine Kinase Receptor C,ETV6-NTRK3 Fusion,Gp145(TrkC),Receptor, trkC,EC 2.7.10,EC:,Neurotrophic Tyrosine Kinase Receptor Type 3,EC
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
TRC-H5256 Human Human TrkC / NTRK3 Protein, Fc Tag (MALS verified)
ACRO Quality

Part of Bioactivity data

TrkC MALS images

The purity of Human TrkC Protein, Fc Tag (Cat. No. TRC-H5256) is more than 90% and the molecular weight of this protein is around 185-215 kDa verified by SEC-MALS.


Immobilized Human NT-3 / Neurotrophin-3 Protein at 2 μg/mL (100 μL/well) can bind Human TrkC Protein, Fc Tag (Cat. No. TRC-H5256) with a linear range of 0.3-5 ng/mL (QC tested).

Synonym Name



TrkC tyrosine kinase is also known as Trk-C receptor, NT-3 growth factor receptor and neurotrophic tyrosine kinase receptor type 3, is a member of the NTRK family which mediates the biological activities of neurotrophins. The primary location of TrkC expression is in the nervous system and, specifically, in regions of the CNS. Low level TrkC expression has also been observed in a wide variety of tissues outside the nervous system. TrkC is part of the large family of receptor tyrosine kinases which includes TrkA and TrkB. Also, there are other neurotrophic factors structurally related to NT-3: NGF, BDNF and NT-4. While TrkB mediates the effects of BDNF, NT-4 and NT-3, TrkA is bound and thereby activated only by NGF. Further, TrkC binds and is activated only by NT-3. TrkB binds BDNF and NT-4 more strongly than it binds NT-3. TrkC binds NT-3 more strongly than TrkB does. Upon neurotrophin binding, TrkC phosphorylates itself and down stream molecules of the related pathways, and therefore mediates the NT3-stimulated neurotrophic effects. This protein thus leads to cell proliferation, differentiation and plays a role in the development of proprioceptive neurons.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Entrectinib NMS-E628; RXDX-101; RG-6268 Approved Nerviano Medical Sciences Srl Rozlytrek, 罗圣全 Japan Carcinoma, Non-Small-Cell Lung Chugai Pharmaceutical Co Ltd 2019-06-18 Cholangiocarcinoma; Melanoma; Thyroid Cancer, Papillary; Carcinoma, Non-Small-Cell Lung; Glioma; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Lymphoproliferative Disorders; Colorectal Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Brain Neoplasms; Solid tumours; Sarcoma; Neuroendocrine Tumors; Central Nervous System Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Neoplasms; Carcinoma, Renal Cell; Hematologic Neoplasms; Skin Melanoma; Ovarian Neoplasms; Head and Neck Neoplasms Details
Larotrectinib sulfate LOXO-101; ARRY-470; BAY-2757556 Approved Array Biopharma Vitrakvi, 维泰凯 United States Solid tumours Bayer Healthcare 2018-11-26 Glioma; Central Nervous System Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Histiocytosis, Langerhans-Cell; Cholangiocarcinoma; Osteosarcoma; Sarcoma, Ewing; Neuroblastoma; Sarcoma; Histiocytic Sarcoma; Colorectal Neoplasms; Neoplasms, Neuroepithelial; Urinary Bladder Neoplasms; Thyroid Neoplasms; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Lymphoma; Uterine Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Neoplasms, Germ Cell and Embryonal; Melanoma; Neuroectodermal Tumors, Primitive, Peripheral; Xanthogranuloma, Juvenile; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Ependymoma; Medulloblastoma; Liver Neoplasms; Fibrosarcoma; Leukemia; Rhabdomyosarcoma; Hematologic Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Hepatoblastoma; Rhabdoid Tumor; Rectal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Wilms Tumor; Colonic Neoplasms; Ski Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Lestaurtinib SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 Phase 3 Clinical Kyowa Hakko Kirin Co Ltd Leukemia, Myeloid; Bone Marrow Neoplasms; Leukemia; Polycythemia Vera; Prostatic Neoplasms; Psoriasis; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neuroblastoma; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential Details
Merestinib 5OGS5K699E; LY-2801653 Phase 2 Clinical Eli Lilly And Company Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
HG-030 HG-030 Phase 1 Clinical Hitgen Inc Solid tumours Details
PBI-200 PBI-200 Phase 1 Clinical Pyramid Biosciences Solid tumours; Desmoplastic Small Round Cell Tumor; Brain Neoplasms Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message